Search results
1 lis 2020 · Lawrie et al. Cochrane review concluded that women who undergo surgical treatment for vH-SIL have about a 50% chance of the condition recurring one year later, irrespective of whether treatment is by surgical excision or laser vaporization [33].
1 sie 2023 · The most common treatment for vulvar intraepithelial neoplasia 3 is surgery to remove the abnormal growth. Typically, this resolves the condition and eliminates the risk of cancer.
4 mar 2014 · The aim of this systematic review was to assess both the risk of progression of VIN III in untreated women and the effect of surgical treatment in relation to recurrences and progression of VIN III.
VIN 3 has a high rate of progression to invasive SCC. Regression of VIN is rare. Proper follow up and treatment of VIN 3 goes a long way in preventing the morbidity associated with vulval cancer. Keywords: Management, Recurrence, VIN3, Vulva. Introduction.
The aim of this randomised clinical trial was to compare the clinical efectiveness, histological response, HPV clearance, acceptance, and psychosexual morbidity of primary imiquimod treatment versus surgical treatment in women with vHSIL.
Laser ablation is acceptable for the treatment of vulvar HSIL (VIN usual type) when cancer is not suspected. It can be used for single, multifocal, or confluent lesions, although the risk of recurrence may be higher than with excision (15, 16).
7 maj 2022 · In The Lancet, Gerda Trutnovsky and colleagues 8 report the first randomised, non-inferiority trial, comparing topical imiquimod therapy with surgical treatment. Per-protocol topical 5% imiquimod treatment was found to be non-inferior to surgical intervention, including excision or laser vaporisation.
